- Home
- BORR vs STOK Comparison
BORR vs STOK Comparison
Compare BORR & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BORR
- STOK
- Stock Information
- Founded
- BORR 2016
- STOK 2014
- Country
- BORR Bermuda
- STOK United States
- Employees
- BORR N/A
- STOK N/A
- Industry
- BORR Oil & Gas Production
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- BORR Energy
- STOK Health Care
- Exchange
- BORR Nasdaq
- STOK Nasdaq
- Market Cap
- BORR 832.9M
- STOK 997.9M
- IPO Year
- BORR 2019
- STOK 2019
- Fundamental
- Price
- BORR $3.02
- STOK $19.63
- Analyst Decision
- BORR Buy
- STOK Strong Buy
- Analyst Count
- BORR 2
- STOK 6
- Target Price
- BORR $9.00
- STOK $26.60
- AVG Volume (30 Days)
- BORR 5.4M
- STOK 1.0M
- Earning Date
- BORR 08-13-2025
- STOK 11-04-2025
- Dividend Yield
- BORR 1.33%
- STOK N/A
- EPS Growth
- BORR N/A
- STOK N/A
- EPS
- BORR 0.20
- STOK 0.91
- Revenue
- BORR $989,000,000.00
- STOK $199,893,000.00
- Revenue This Year
- BORR $8.35
- STOK $415.58
- Revenue Next Year
- BORR $6.39
- STOK N/A
- P/E Ratio
- BORR $13.96
- STOK $21.64
- Revenue Growth
- BORR 7.73
- STOK 1218.82
- 52 Week Low
- BORR $1.55
- STOK $5.35
- 52 Week High
- BORR $5.82
- STOK $20.45
- Technical
- Relative Strength Index (RSI)
- BORR 68.10
- STOK 74.96
- Support Level
- BORR $2.71
- STOK $19.07
- Resistance Level
- BORR $2.62
- STOK $20.45
- Average True Range (ATR)
- BORR 0.17
- STOK 1.01
- MACD
- BORR 0.02
- STOK -0.04
- Stochastic Oscillator
- BORR 98.68
- STOK 76.90
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.